Roivant Sciences Ltd
For the period ended Dec 31, 2024. Filed Feb 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2024 · Filed Feb 10, 2025
ROIV$38.88+6.2%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Dated: February 10, 2025 | ROIVANT SCIENCES LTD. | |
|---|---|---|
| By: | /s/ Matthew Gline | |
| Name: Matthew Gline | ||
| Title: Principal Executive Officer | ||
| By: | /s/ Richard Pulik | |
| Name: Richard Pulik | ||
| Title: Principal Financial Officer | ||
| By: | /s/ Keyur Parekh | |
| Name: Keyur Parekh | ||
| Title: Authorized Signatory | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.